focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 22nd Aug 2013 07:25

Aggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged.Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating.BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendation.Cairn Energy: RBC Capital moves target price from 440p to 450p and reiterates its outperform rating.Cropper (James): Westhouse Securities ups target price from 300p to 350p, while downgrading to add.Faroe Petroleum: Liberum Capital lowers target price from 188p to 183p, while leaving its buy recommendation unchanged.Ferrexpo: Cantor Fitzgerald reduces target price from 373p to 290p, but stays with its buy recommendation.Glencore Xstrata: JP Morgan cuts target price from 410p to 390p retaining its overweight rating.Hikma Pharmaceuticals: Jefferies ups target price from 1200p to 1250p and keeps a buy recommendation.Hochschild Mining: Westhouse Securities increases target price from 150p to 200p and reiterates a neutral rating. JP Morgan moves target price from 75p to 80p, while keeping an underweight rating. Citi shifts target price from 133p to 132p and maintains its sell recommendation. RBC Capital ups target price from 220p to 260p and stays with its neutral rating.IMI: Investec places both its target price (prev.: 1350p) and its hold recommendation under review.Intertek Group: Credit Suisse reduces target price from 3850p to 3600p, while retaining an outperform rating.IP Group: Numis lowers target price from 129p to 124p, while its hold recommendation remains unchanged.John Wood Group: JP Morgan cuts target price from 963p to 951p and stays with its neutral rating. Liberum Capital reduces target price from 892p to 874p.Legal & General Group: Morgan Stanley moves target price from 184p to 192p and maintains an equal-weight rating.Lloyds Banking Group: Jefferies shifts target price from 65p to 69p reiterating a hold recommendation.Sportech: Investec lowers target price from 110p to 105p and leaves its buy recommendation unaltered.Stagecoach Group: Deutsche Bank raises target price from 330p to 350p staying with its buy recommendation.Summit Corporation: N+1 Singer shifts target price from 8.80p to 10.70p keeping its buy recommendation.Vitec Group: Investec increases target price from 740 to 810p and retains a buy recommendation.Wolseley: UBS upgrades from neutral to buy with a target price of 3500p.
More News
24 Feb 2016 12:35

Summit Therapeutics hails strong C-difficile findings

(ShareCast News) - Summit Therapeutics has reported that pre-clinical research into its treatment for the Clostridium difficile hospital superbug has found it to be a "novel and potent antibiotic". A peer-reviewed paper has been produced based on a study of Summit's ridinilazole versus current stand

Read more
19 Jan 2016 12:48

Summit Therapeutics gains worldwide patent protection for C-diff drug

(ShareCast News) - Summit Therapeutics has won a key patent protecting its novel antibiotic, ridinilazole, for the treatment of infections caused by the Clostridium difficile hospital superbug. The patent will grant Summit exclusivity in Europe for the use of ridinilazole in the treatment of CDI unt

Read more
19 Jan 2016 12:18

Summit Therapeutics Gets European Patent For Antibiotic Ridinilazole

Read more
22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

Read more
17 Dec 2015 12:28

Summit Therapeutics Third Quarter Loss Widens As Pipeline Progresses

Read more
17 Nov 2015 12:17

Summit Therapeutics Extends Alliance With University Of Oxford

Read more
18 Sep 2015 12:50

Summit Therapeutics To Present Positive SMT19969 Data In San Diego

Read more
10 Sep 2015 11:11

Summit Therapeutics Finishes Enrolment For Phase II SMT19969 Trial

Read more
27 Aug 2015 11:48

Summit Therapeutics First Half Loss Widens As It Develops Pipeline

Read more
17 Aug 2015 12:33

Summit Therapeutics surges on positive clinical trial update

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial. The drug discovery and development company said half of the

Read more
14 Jul 2015 07:25

LONDON BRIEFING: Iran Nuclear Agreement Hits Oil Prices

Read more
13 Jul 2015 11:23

Summit Therapeutics Says Preclincal Data Support Its DMD Treatment

Read more
8 Jul 2015 12:04

Summit Therapeutics receives FDA fast-track decision for new antibiotic

Drug discovery and development company Summit Therapeutics has received approval from the US and Food Drug Administration (FDA) for its novel antibiotic. The FDA granted fast-track designation for the SMT19969 antibiotic which treats both duchenne muscular dystrophy and C. difficile infection (CDI).

Read more
8 Jul 2015 11:22

Summit Therapeutics Says CDI Antibiotic Given Fast Track Designation

Read more
7 Jul 2015 11:24

Summit Therapeutics Gets European Patent For Muscle Disease Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.